Tweet by ScienceofParkinsons on Twitter Posted byJoseph Thornton MDMay 10, 2022Posted inBlog ScienceofParkinsons @ScienceofPD WOW – A Phase 3 randomized clinical trial enrolling 130 participants with early-stage #ALS & moderate progression rate finds ultrahigh-dose methylcobalamin (vitamin B₁₂) significantly slowed progression (ALSFRS-R total score) over 16-week study jamanetwork.com/journals/jaman… pic.twitter.com/jOA1Q1zbj6 5/10/22, 7:46 AM Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Like Loading... Related Published by Joseph Thornton MD Teacher, Clinical Supervisor Clinical Associate Professor, Psychiatry University of Florida Affiliation is for identification only. All content and opinions are my own. View more posts
Gator Psychiatry 